Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimian Group ABVIMGF 70 EV-to-EBIT is 22.41 as of Jul. 24, 2026, which is 51% below its 10-year median of 45.85. GuruFocus rates VIMGF with a GF Score™ of 70/100 and a GF Value™ of $2.90. The stock has 2 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Vimian Group AB ranks worse than 51.92% on this metric.
Vimian Group AB (OTCPK:VIMGF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vimian Group AB's Enterprise Value for the quarter that ended in Jun. 2026 was $1,736.4 Mil.
Vimian Group AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $93.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB EV-to-EBIT Related Terms
Vimian Group AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimian Group AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's EV-to-EBIT falls into.
Vimian Group AB's current Enterprise Value is $2,091.4 Mil.
Vimian Group AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $93.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a EV-to-EBIT of 22.41 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vimian Group AB and its competitors. This is 51% below median its historical median of 45.85. Over the past decade, Vimian Group AB's EV-to-EBIT has ranged from 21.02 to 162.63. According to the industry distribution chart, Vimian Group AB ranks #54 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 51.9%.
Is Vimian Group AB's EV-to-EBIT too high?
Vimian Group AB's current EV-to-EBIT of 22.41 is 51% below median its 10-year median of 45.85. Over the past 10 years, this metric has ranged from a low of 21.02 to a high of 162.63. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.57. Vimian Group AB's value of 22.41 is 0.7% below this industry median. Based on the distribution chart, Vimian Group AB ranks #54 out of 104 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #54 out of 104 companies for EV-to-EBIT. This places Vimian Group AB in the lower half of its industry. The industry median EV-to-EBIT is 22.57. Vimian Group AB's value of 22.41 is 0.7% below this benchmark. Historically, Vimian Group AB's own EV-to-EBIT has ranged from 21.02 to 162.63 over the past decade. While the company's 10-year median is 45.85 vs. the industry median of 22.57, Vimian Group AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.57, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current EV-to-EBIT of 22.41 is 0.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current EV-to-EBIT is 22.41, which is 51% below median its own 10-year median of 45.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current EV-to-EBIT of 22.41. The stock's GF Value™ is $2.90, compared to a current price of $2.77 — trading 4.5% below its estimated fair value. The current EV-to-EBIT is 22.41, which is 51% below median its 10-year median of 45.85 and 0.7% below the Medical Diagnostics & Research industry median of 22.57. Vimian Group AB's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current EV-to-EBIT is 22.41 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 4.5% below its estimated GF Value™ of $2.90.
Key valuation signals for VIMGF:
EV-to-EBIT: 22.41 (51% below median its 10-year median of 45.85)
GF Value™: $2.90 vs. price of $2.77 (4.5% below fair value)
Industry Position: 0.7% below the Medical Diagnostics & Research median (#54 of 104)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
70GF Score
Get the complete analysis for VIMGF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
